Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2000 1
2006 3
2007 1
2008 1
2012 2
2013 2
2015 1
2017 1
2018 2
2019 2
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Obesity due to pro-opiomelanocortin deficiency"
Page 1
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Clément K, et al. Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8. Epub 2020 Oct 30. Lancet Diabetes Endocrinol. 2020. PMID: 33137293 Clinical Trial.
We report the results from trials of the MC4R agonist setmelanotide in individuals with severe obesity due to either pro-opiomelanocortin (POMC) deficiency obesity or leptin receptor (LEPR) deficiency obesity. ...INTERPRETATION: Ou …
We report the results from trials of the MC4R agonist setmelanotide in individuals with severe obesity due to either pro-op …
Pro-opiomelanocortin (POMC) deficiency and peripheral melanocortins in obesity.
Zemel MB, Shi H. Zemel MB, et al. Nutr Rev. 2000 Jun;58(6):177-80. doi: 10.1111/j.1753-4887.2000.tb01857.x. Nutr Rev. 2000. PMID: 10885325 Review.
Melanocortin peptides, derived from pro-opiomelanocortin (POMC), appear to play a significant role in appetite and body weight regulation. ...Recently, Pomc knockout mice were generated and shown to develop hyperphagia and obesity with a time-course an …
Melanocortin peptides, derived from pro-opiomelanocortin (POMC), appear to play a significant role in appetite and body weight …
Updates on Monogenic Obesity in a Multifactorial Disease.
Baxter J, Armijo PR, Flores L, Krause C, Samreen S, Tanner T. Baxter J, et al. Obes Surg. 2019 Dec;29(12):4077-4083. doi: 10.1007/s11695-019-04200-z. Obes Surg. 2019. PMID: 31641982 Review.
Thus, this narrative review focused on four genes which have genome-wide association study-documented links to obesity and obesity syndromes. We explored their involvement in the predisposition, progression, and prognosis of obesity. Leptin, leptin rec …
Thus, this narrative review focused on four genes which have genome-wide association study-documented links to obesity and obesity …
Etiology and pathogenesis of obesity.
Bray GA. Bray GA. Clin Cornerstone. 1999;2(3):1-15. doi: 10.1016/s1098-3597(99)90001-7. Clin Cornerstone. 1999. PMID: 10696281 Review.
Leptin deficiency and defects in the leptin receptor both produce human obesity. Defects in the pro-opiomelanocortin receptor system, the peroxisome proliferator-activated receptor-gamma, the agouti-related peptide, and a few other rare genetic syndrom …
Leptin deficiency and defects in the leptin receptor both produce human obesity. Defects in the pro-opiomelanocortin …
Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
Ayers KL, Glicksberg BS, Garfield AS, Longerich S, White JA, Yang P, Du L, Chittenden TW, Gulcher JR, Roy S, Fiedorek F, Gottesdiener K, Cohen S, North KE, Schadt EE, Li SD, Chen R, Van der Ploeg LHT. Ayers KL, et al. J Clin Endocrinol Metab. 2018 Jul 1;103(7):2601-2612. doi: 10.1210/jc.2018-00258. J Clin Endocrinol Metab. 2018. PMID: 29726959 Free PMC article.
Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), or MC4R genes, have been shown to cause early-onset severe obesity. ...RESULTS: We predic …
Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone conve …
Hypothalamic-Pituitary Disorders in Childhood Cancer Survivors: Prevalence, Risk Factors and Long-Term Health Outcomes.
van Iersel L, Li Z, Srivastava DK, Brinkman TM, Bjornard KL, Wilson CL, Green DM, Merchant TE, Pui CH, Howell RM, Smith SA, Armstrong GT, Hudson MM, Robison LL, Ness KK, Gajjar A, Krull KR, Sklar CA, van Santen HM, Chemaitilly W. van Iersel L, et al. J Clin Endocrinol Metab. 2019 Dec 1;104(12):6101-6115. doi: 10.1210/jc.2019-00834. J Clin Endocrinol Metab. 2019. PMID: 31373627 Free PMC article.
OBJECTIVE: To describe prevalence, risk factors, and associated adverse health outcomes of deficiencies in GH deficiency (GHD), TSH deficiency (TSHD), LH/FSH deficiency (LH/FSHD), and ACTH deficiency (ACTHD), and central precocious puberty (CPP) …
OBJECTIVE: To describe prevalence, risk factors, and associated adverse health outcomes of deficiencies in GH deficiency (GHD) …
A Melanocortin-4 Receptor Agonist Induces Skin and Hair Pigmentation in Patients with Monogenic Mutations in the Leptin-Melanocortin Pathway.
Kanti V, Puder L, Jahnke I, Krabusch PM, Kottner J, Vogt A, Richter C, Andruck A, Lechner L, Poitou C, Krude H, Gottesdiener K, Clément K, Farooqi IS, Wiegand S, Kühnen P, Blume-Peytavi U. Kanti V, et al. Skin Pharmacol Physiol. 2021;34(6):307-316. doi: 10.1159/000516282. Epub 2021 May 31. Skin Pharmacol Physiol. 2021. PMID: 34058738 Clinical Trial.
Dermatological examination, dermoscopy, whole body photographic documentation, and spectrophotometric measurements were performed at screening visit and approximately every 3 months during the course of the study. RESULTS: We report the results of a maximum treatment durat …
Dermatological examination, dermoscopy, whole body photographic documentation, and spectrophotometric measurements were performed at screeni …
Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans.
Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A. Krude H, et al. Nat Genet. 1998 Jun;19(2):155-7. doi: 10.1038/509. Nat Genet. 1998. PMID: 9620771
Sequential cleavage of the precursor protein pre-pro-opiomelanocortin (POMC) generates the melanocortin peptides adrenocorticotrophin (ACTH), melanocyte-stimulating hormones (MSH) alpha, beta and gamma as well as the opioid-receptor ligand beta-endorphin. ...The dua …
Sequential cleavage of the precursor protein pre-pro-opiomelanocortin (POMC) generates the melanocortin peptides adrenocortico …
Assessment of the 21-hydroxylase deficiency and the adrenal functions in young females with Turner syndrome.
Onder A, Aycan Z, Cetinkaya S, Kendirci HN, Bas VN, Agladioglu SY. Onder A, et al. J Pediatr Endocrinol Metab. 2012;25(7-8):681-5. doi: 10.1515/jpem-2012-0052. J Pediatr Endocrinol Metab. 2012. PMID: 23155693 Clinical Trial.
The aim of this study was to evaluate the incidence of 21-hydroxylase deficiency in patients with TS in our population. 21-hydroxylase deficiency was evaluated in 44 TS cases with 45X (n=20) and 24 mosaic cases. ...The basal and peak 17OHP cortisol levels were not c …
The aim of this study was to evaluate the incidence of 21-hydroxylase deficiency in patients with TS in our population. 21-hydroxylas …
Diagnosis and treatment of pituitary microadenoma: report of 80 cases.
Zhang HW, Sun W, Yang J, Yan CX, Yu CJ. Zhang HW, et al. Neurol Res. 2008 Jul;30(6):587-93. doi: 10.1179/174313208X310287. Neurol Res. 2008. PMID: 18647498 Clinical Trial.
Diabetes insipidus occurred in 19 patients, among which 15 patients recovered in 1 week, three in 1 month and one in 7 months. The adrenocorticotrophic hormone deficiency was found in nine of 63 patients with PRL-, GH- and non-functioning microadenoma (12%), but hypoadrena …
Diabetes insipidus occurred in 19 patients, among which 15 patients recovered in 1 week, three in 1 month and one in 7 months. The adrenocor …
20 results